MedTrace Logo

Dose Ranging Study

NCT01802723 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 472

Last updated 2015-03-26

No results posted yet for this study

Summary

Dose Ranging Study

Conditions

  • Periumbilical Subcutaneous Adipose Tissue Reduction

Interventions

DRUG

Drug: salmeterol xinafoate

DRUG

Drug: Placebo

Sponsors & Collaborators

  • Neothetics, Inc

    lead INDUSTRY

Principal Investigators

  • Murray C Maytom, MBChB, MBA · Neothetics, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-06-30
Completion
2013-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01802723 on ClinicalTrials.gov